SimpleXMLElement Object ( [PubmedArticle] => Array ( [0] => SimpleXMLElement Object ( [MedlineCitation] => SimpleXMLElement Object ( [@attributes] => Array ( [Status] => Publisher [Owner] => NLM ) [PMID] => 33631867 [DateRevised] => SimpleXMLElement Object ( [Year] => 2021 [Month] => 02 [Day] => 25 ) [Article] => SimpleXMLElement Object ( [@attributes] => Array ( [PubModel] => Print-Electronic ) [Journal] => SimpleXMLElement Object ( [ISSN] => 1447-0756 [JournalIssue] => SimpleXMLElement Object ( [@attributes] => Array ( [CitedMedium] => Internet ) [PubDate] => SimpleXMLElement Object ( [Year] => 2021 [Month] => Feb [Day] => 25 ) ) [Title] => The journal of obstetrics and gynaecology research [ISOAbbreviation] => J Obstet Gynaecol Res ) [ArticleTitle] => Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2017 and annual treatment report for 2012. [ELocationID] => 10.1111/jog.14724 [Abstract] => SimpleXMLElement Object ( [AbstractText] => Array ( [0] => To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2017 and the Annual Treatment Report for 2012, on the outcomes of patients who started treatment in 2012. [1] => The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2017 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial and ovarian cancer in 2012 was analyzed by using the Kaplan-Meier, log-rank and Wilcoxon tests. [2] => Treatment was initiated in 2017 for 7710 patients with cervical cancer; 11 120 with endometrial cancer; 7029 with ovarian, tubal and peritoneal cancer; 2164 with ovarian borderline tumors; and with the others (213 vulvar cancer, 139 vaginal cancer, 366 uterine sarcoma, 41 uterine adenosarcoma and 131 trophoblastic diseases). This clinicopathological information was summarized as the patient annual report. The 5-year survival rates of the patients with cervical cancer were 92.9, 75.5, 58.2 and 26.7% for stages I, II, III and IV, respectively. The 5-year survival rates for the patients with endometrial cancer were 93.6, 85.6, 72.6 and 27.3% for stages I, II, III and IV, respectively. The 5-year survival rates for the patients with ovarian cancer (surface epithelial-stromal tumors) were 92.5, 83.5, 49.5 and 30.8% for stages I, II, III and IV, respectively. [3] => The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan. ) [CopyrightInformation] => © 2021 Japan Society of Obstetrics and Gynecology. ) [AuthorList] => SimpleXMLElement Object ( [@attributes] => Array ( [CompleteYN] => Y ) [Author] => Array ( [0] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Nagase [ForeName] => Satoru [Initials] => S [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Obstetrics and Gynecology, Yamagata University, Faculty of Medicine, Yamagata, Japan. ) ) [1] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Ohta [ForeName] => Tsuyoshi [Initials] => T [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Obstetrics and Gynecology, Yamagata University, Faculty of Medicine, Yamagata, Japan. ) ) [2] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Takahashi [ForeName] => Fumiaki [Initials] => F [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Information Science, Iwate Medical University, Morioka, Japan. ) ) [3] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Yaegashi [ForeName] => Nobuo [Initials] => N [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Gynecology and Obstetrics, Tohoku University Graduate School of Medicine, Sendai, Japan. ) ) [4] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [CollectiveName] => Board members of the 2020 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology ) ) ) [Language] => eng [PublicationTypeList] => SimpleXMLElement Object ( [PublicationType] => Journal Article ) [ArticleDate] => SimpleXMLElement Object ( [@attributes] => Array ( [DateType] => Electronic ) [Year] => 2021 [Month] => 02 [Day] => 25 ) ) [MedlineJournalInfo] => SimpleXMLElement Object ( [Country] => Australia [MedlineTA] => J Obstet Gynaecol Res [NlmUniqueID] => 9612761 [ISSNLinking] => 1341-8076 ) [CitationSubset] => IM [KeywordList] => SimpleXMLElement Object ( [@attributes] => Array ( [Owner] => NOTNLM ) [Keyword] => Array ( [0] => Japan [1] => annual report [2] => cervical cancer [3] => endometrial cancer [4] => gynecologic cancer [5] => ovarian [6] => tubal and peritoneal cancer ) ) ) [PubmedData] => SimpleXMLElement Object ( [History] => SimpleXMLElement Object ( [PubMedPubDate] => Array ( [0] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => received ) [Year] => 2020 [Month] => 12 [Day] => 01 ) [1] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => accepted ) [Year] => 2021 [Month] => 02 [Day] => 11 ) [2] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => entrez ) [Year] => 2021 [Month] => 2 [Day] => 25 [Hour] => 20 [Minute] => 19 ) [3] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => pubmed ) [Year] => 2021 [Month] => 2 [Day] => 26 [Hour] => 6 [Minute] => 0 ) [4] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => medline ) [Year] => 2021 [Month] => 2 [Day] => 26 [Hour] => 6 [Minute] => 0 ) ) ) [PublicationStatus] => aheadofprint [ArticleIdList] => SimpleXMLElement Object ( [ArticleId] => Array ( [0] => 33631867 [1] => 10.1111/jog.14724 ) ) [ReferenceList] => SimpleXMLElement Object ( [Title] => References [Reference] => Array ( [0] => SimpleXMLElement Object ( [Citation] => Enomoto T. The patients annual report in 2017. Acta Obstet Gynecol Jpn. 2019;71:669-724. ) [1] => SimpleXMLElement Object ( [Citation] => Enomoto T. The treatment annual report in 2010. Acta Obstet Gynecol Jpn. 2019;71:725-803. ) [2] => SimpleXMLElement Object ( [Citation] => Nagase S, Ohta T, Takahashi F, Enomoto T, 2017 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology. Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patients report for 2015 and annual treatment report for 2010. J Obstet Gynaecol Res. 2019;45:289-98. https://doi.org/10.1111/jog.13863. ) [3] => SimpleXMLElement Object ( [Citation] => Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018;379:1895-904. https://doi.org/10.1056/NEJMoa1806395. ) [4] => SimpleXMLElement Object ( [Citation] => Wollinga T, Ezendam NPM, Eggink FA, Smink M, van Hamont D, Pijlman B, et al. Implementation of laparoscopic hysterectomy for endometrial cancer over the past decade. Gynecol Surg. 2018;15(1):7. https://doi.org/10.1186/s10397-018-1040-x. ) [5] => SimpleXMLElement Object ( [Citation] => American Cancer Society. https://www.cancer.org/ ) ) ) ) ) [1] => SimpleXMLElement Object ( [MedlineCitation] => SimpleXMLElement Object ( [@attributes] => Array ( [Status] => Publisher [Owner] => NLM ) [PMID] => 33631841 [DateRevised] => SimpleXMLElement Object ( [Year] => 2021 [Month] => 02 [Day] => 25 ) [Article] => SimpleXMLElement Object ( [@attributes] => Array ( [PubModel] => Electronic ) [Journal] => SimpleXMLElement Object ( [ISSN] => 1469-493X [JournalIssue] => SimpleXMLElement Object ( [@attributes] => Array ( [CitedMedium] => Internet ) [Volume] => 2 [PubDate] => SimpleXMLElement Object ( [Year] => 2021 [Month] => Feb [Day] => 25 ) ) [Title] => The Cochrane database of systematic reviews [ISOAbbreviation] => Cochrane Database Syst Rev ) [ArticleTitle] => Belimumab for systemic lupus erythematosus. [Pagination] => SimpleXMLElement Object ( [MedlinePgn] => CD010668 ) [ELocationID] => 10.1002/14651858.CD010668.pub2 [Abstract] => SimpleXMLElement Object ( [AbstractText] => Array ( [0] => Belimumab, the first biologic approved for the treatment of systemic lupus erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE and help control disease activity. [1] => To assess the benefits and harms of belimumab (alone or in combination) in systematic lupus erythematosus. [2] => An Information Specialist carried out the searches of CENTRAL, MEDLINE, Embase, CINAHL, Web of Science, the World Health Organization (WHO) International Clinical Trials Registry Platform, and clinicaltrials.gov from inception to 25 September 2019. There were no language or date restrictions. [3] => We included randomized controlled trials (RCTs) or controlled clinical trials (CCTs) of belimumab (alone or in combination) compared to placebo/control treatment (immunosuppressive drugs, such as azathioprine, cyclosporine, mycophenolate mofetil or another biologic), in adults with SLE. [4] => We used standard methodologic procedures expected by Cochrane. [5] => Six RCTs (2917 participants) qualified for quantitative analyses. All included studies were multicenter, international or US-based. The age range of the included participants was 22 to 80 years; most were women; and study duration ranged from 84 days to 76 weeks. The risk of bias was generally low except for attrition bias, which was high in 67% of studies. Compared to placebo, more participants on belimumab 10 mg/kg (Food and Drug Administration (FDA)-approved dose) showed at least a 4-point improvement (reduction) in Safety of Estrogen in Lupus National Assessment (SELENA) - Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, a validated SLE disease activity index: (risk ratio (RR) 1.33, 95% confidence interval (CI) 1.22 to 1.45; 829/1589 in belimumab group and 424/1077 in placebo; I= 0%; 4 RCTs; high-certainty evidence). Change in health-related quality of life (HRQOL), assessed by Short Form-36 Physical Component Summary score improvement (range 0 to 100), showed there was probably little or no difference between groups (mean difference 1.6 points, 95% CI 0.30 to 2.90; 401 in belimumab group and 400 in placebo; I= 0%; 2 RCTs; moderate-certainty evidence). The belimumab 10 mg/kg group showed greater improvement in glucocorticoid dose, with a higher proportion of participants reducing their dose by at least 50% compared to placebo (RR 1.59, 95% CI 1.17 to 2.15; 81/269 in belimumab group and 52/268 in placebo; I= 0%; 2 RCTs; high-certainty evidence). The proportion of participants experiencing harm may not differ meaningfully between the belimumab 10 mg/kg and placebo groups: one or more serious adverse event (RR 0.87, 95% CI: 0.68 to 1.11; 238/1700 in belimumab group and 199/1190 in placebo; I= 48%; 5 RCTs; low-certainty evidence; ); one or more serious infection (RR 1.01, 95% CI: 0.66 to 1.54; 44/1230 in belimumab group and 40/955 in placebo; I= 0%; 4 RCTs; moderate-certainty evidence); and withdrawals due to adverse events (RR 0.82, 95% CI: 0.63 to 1.07; 113/1700 in belimumab group and 94/1190 in placebo; I= 0%; 5 RCTs; moderate-certainty evidence). Mortality was rare, and may not differ between belimumab 10 mg/kg and placebo (Peto odds ratio 1.15, 95% CI 0.41 to 3.25; 9/1714 in belimumab group and 6/1203 in placebo; I= 4%; 6 RCTs; low-certainty evidence). [6] => The six studies that provided evidence for benefits and harms of belimumab were well-designed, high-quality RCTs. At the FDA-approved dose of 10 mg/kg, based on moderate to high-certainty data, belimumab was probably associated with a clinically meaningful efficacy benefit compared to placebo in participants with SLE at 52 weeks. Evidence related to harms is inconclusive and mostly of moderate to low-certainty evidence. More data are needed for the longer-term efficacy of belimumab. ) [CopyrightInformation] => Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ) [AuthorList] => SimpleXMLElement Object ( [@attributes] => Array ( [CompleteYN] => Y ) [Author] => Array ( [0] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Singh [ForeName] => Jasvinder A [Initials] => JA [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Medicine, Birmingham VA Medical Center, Birmingham, AL, USA. ) ) [1] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Shah [ForeName] => Nipam P [Initials] => NP [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA. ) ) [2] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Mudano [ForeName] => Amy S [Initials] => AS [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Medicine - Rheumatology, University of Alabama at Birmingham, Birmingham, USA. ) ) ) ) [Language] => eng [PublicationTypeList] => SimpleXMLElement Object ( [PublicationType] => Array ( [0] => Journal Article [1] => Review ) ) [ArticleDate] => SimpleXMLElement Object ( [@attributes] => Array ( [DateType] => Electronic ) [Year] => 2021 [Month] => 02 [Day] => 25 ) ) [MedlineJournalInfo] => SimpleXMLElement Object ( [Country] => England [MedlineTA] => Cochrane Database Syst Rev [NlmUniqueID] => 100909747 [ISSNLinking] => 1361-6137 ) [CitationSubset] => IM ) [PubmedData] => SimpleXMLElement Object ( [History] => SimpleXMLElement Object ( [PubMedPubDate] => Array ( [0] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => entrez ) [Year] => 2021 [Month] => 2 [Day] => 25 [Hour] => 20 [Minute] => 19 ) [1] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => pubmed ) [Year] => 2021 [Month] => 2 [Day] => 26 [Hour] => 6 [Minute] => 0 ) [2] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => medline ) [Year] => 2021 [Month] => 2 [Day] => 26 [Hour] => 6 [Minute] => 0 ) ) ) [PublicationStatus] => epublish [ArticleIdList] => SimpleXMLElement Object ( [ArticleId] => Array ( [0] => 33631841 [1] => 10.1002/14651858.CD010668.pub2 ) ) [ReferenceList] => SimpleXMLElement Object ( [Title] => References [ReferenceList] => Array ( [0] => SimpleXMLElement Object ( [Title] => References to studies included in this review [ReferenceList] => Array ( [0] => SimpleXMLElement Object ( [Title] => Furie 2008 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Research and Therapy 2008;5:R109. ) ) [1] => SimpleXMLElement Object ( [Title] => Furie 2011 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis and Rheumatism 2011;63(12):3918-30. ) ) [2] => SimpleXMLElement Object ( [Title] => Navarra 2011 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9767):721-31. ) ) [3] => SimpleXMLElement Object ( [Title] => Stohl 2017 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer A, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus. Arthritis and Rheumatism 2017;69(5):1016-27. ) ) [4] => SimpleXMLElement Object ( [Title] => Wallace 2009 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis and Rheumatism 2009;61(9):1168-78. ) ) [5] => SimpleXMLElement Object ( [Title] => Zhang 2018 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Zhang F, Bae S-C, Bass D, Chu M, Egginton S, Gordon D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Annals of the Rheumatic Diseases 2018;77:355-63. ) ) ) ) [1] => SimpleXMLElement Object ( [Title] => References to studies excluded from this review [ReferenceList] => Array ( [0] => SimpleXMLElement Object ( [Title] => Brunner 2018 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, et al. Efficacy and safety of intravenous belimumab in children with systemic lupus erythematosus. Arthritis and Rheumatology 2018;70(Supplement 9):3225-6. ) ) [1] => SimpleXMLElement Object ( [Title] => Cervera 2011 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Cervera R, Strand V, Levy RA, Petri M, Rudge H, Hough D, et al. Belimumab improved fatigue and SF-36 physical/mental component summary scores in SLE: BLISS-52/BLISS-76. Lupus 2011;20(4):425. ) ) [2] => SimpleXMLElement Object ( [Title] => Chatham 2012 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. Journal of Rheumatology 2012;39(8):1632-40. ) ) [3] => SimpleXMLElement Object ( [Title] => D'Cruz 2013 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => D'Cruz D, Gladman D, Navarra SV, Sanchez-Guerrero J, Manzi S, Freimuth WW. Post Hoc British Isles Lupus Assessment Group Index musculoskeletal organ domain analysis of systemic lupus erythematosus patients in phase 3 belimumab trials. Lupus 2013;22(1):106. ) ) [4] => SimpleXMLElement Object ( [Title] => Dooley 2013 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Dooley MA, Houssiau F, Aranow C, D'Cruz DP, Askanase A, Roth DA, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013;22(1):63-72. ) ) [5] => SimpleXMLElement Object ( [Title] => Doria 2018 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Doria A, Bass D, Schwarting A, Hammer A, Gordon D, Scheinberg M, et al. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. Lupus 2018;27(9):1489-98. ) ) [6] => SimpleXMLElement Object ( [Title] => Furie 2018 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, et al. Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: a continuation of a seventy-six-week phase III parent study in the United States. Arthritis and Rheumatology 2018;70(6):868-77. ) ) [7] => SimpleXMLElement Object ( [Title] => Gamble 2012 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Gamble RG, Dellavalle RP. A randomized controlled trial of belimumab for the treatment of active systemic lupus erythematosus. Archives of Dermatology 2012;148(3):376-8. ) ) [8] => SimpleXMLElement Object ( [Title] => Jacobi 2010 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis and Rheumatism 2010;62(1):201-10. ) ) [9] => SimpleXMLElement Object ( [Title] => Manzi 2011 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Manzi S, Gladman D, Navarra S, Sanchez-Guerrero J, D'Cruz D, Freimuth W, et al. Post Hoc British Isles Lupus Assessment Group Index mucocutaneous organ domain item analysis of systemic lupus erythematosus patients treated in phase 3 belimumab clinical trials.. Arthritis and Rheumatism 2011;63 (10 Suppl):S231. ) ) [10] => SimpleXMLElement Object ( [Title] => Manzi 2012 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Annals of the Rheumatic Diseases 2012;71(11):1833-8. ) ) [11] => SimpleXMLElement Object ( [Title] => Merrill 2012 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Merrill JT, Ginzler EM, Wallace DJ, McKay JD, Lisse JR, Aranow C, et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis and Rheumatism 2012;64(10):3364-73. ) ) [12] => SimpleXMLElement Object ( [Title] => Onno‐Teng 2019 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Teng YK, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open 2019;9(3):e025687. ) ) [13] => SimpleXMLElement Object ( [Title] => Petri 2013 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Petri MA, Van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis and Rheumatism 2013;65(8):2143-53. ) ) [14] => SimpleXMLElement Object ( [Title] => Rademacher 2018 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Rademacher JG, Schrempf LE, Pluss M, Muller GA, Korsten P. Therapeutic efficacy of belimumab in addition to standard therapy for lupus nephritis and neuropsychiatric lupus-case series of routinely collected data at a single centre. Lupus Science and Medicine 2018;5(Supplement 1):A119-20. ) ) [15] => SimpleXMLElement Object ( [Title] => Stohl 2012 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis and Rheumatism 2012;64(7):2328-37. ) ) [16] => SimpleXMLElement Object ( [Title] => Strand 2014 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Annals of the Rheumatic Diseases May 2014;73(5):838-44. ) ) [17] => SimpleXMLElement Object ( [Title] => Strand 2019 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Strand V, Berry P, Lin X, Asukai Y, Punwaney R, Ramachandran S. Long-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: six years of treatment. Arthritis Care and Research 2019;71(6):829-38. ) ) [18] => SimpleXMLElement Object ( [Title] => van Vollenhoven 2012 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Annals of the Rheumatic Diseases 2012;71(8):1343-9. ) ) [19] => SimpleXMLElement Object ( [Title] => van Vollenhoven 2019 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, et al. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. Rheumatology 2019;59(2):281-91. ) ) [20] => SimpleXMLElement Object ( [Title] => von Kempis 2019 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => von Kempis J, Duetsch S, Reuschling N, Villiger R, Villiger PM, Vallelian F, et al. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland. Swiss Medical Weekly 2019;149:w20022. ) ) [21] => SimpleXMLElement Object ( [Title] => Wallace 2013 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus 2013;22(2):144-54. ) ) [22] => SimpleXMLElement Object ( [Title] => Wallace 2019 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. Arthritis and Rheumatology 2019;71(7):1125-34. ) ) ) ) [2] => SimpleXMLElement Object ( [Title] => References to studies awaiting assessment [ReferenceList] => Array ( [0] => SimpleXMLElement Object ( [Title] => D'Cruz 2019 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => D'Cruz D, Maksimowicz-McKinnon K, Oates J, Santiago MB, Bass D, Burriss S, et al. Efficacy and safety of belimumab in patients of black race with systemic lupus erythematosus: Results from the embrace study. Lupus Science and Medicine 2019;6(Supplement 1):A149-50. ) ) [1] => SimpleXMLElement Object ( [Title] => Tanaka 2017 {published data only} [Reference] => SimpleXMLElement Object ( [Citation] => Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Pobiner B, et al. Effects of belimumab on corticosteroid use in a pivotal phase III, randomised, placebo controlled study in subjects with systemic lupus erythematosus in North East Asia. Lupus Science and Medicine 2017;4(Supplement 1):A45-6. ) ) ) ) [3] => SimpleXMLElement Object ( [Title] => Additional references [ReferenceList] => Array ( [0] => SimpleXMLElement Object ( [Title] => Blair 2018 [Reference] => SimpleXMLElement Object ( [Citation] => Blair HA, Duggan ST. Belimumab: a review in systemic lupus erythematosus. Drugs 2018;78(3):355-66. ) ) [1] => SimpleXMLElement Object ( [Title] => Bossen 2006 [Reference] => SimpleXMLElement Object ( [Citation] => Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Seminars in Immunology 2006;18(5):263-75. ) ) [2] => SimpleXMLElement Object ( [Title] => Boyce 2012 [Reference] => SimpleXMLElement Object ( [Citation] => Boyce EG, Fusco BE. Belimumab: review of use in systemic lupus erythematosus. Clinical Therapeutics 2012;34(5):1006-22. ) ) [3] => SimpleXMLElement Object ( [Title] => Burness 2011 [Reference] => SimpleXMLElement Object ( [Citation] => Burness CB, McCormack PL. Belimimab: in systemic lupus erythematosus. Drugs 2011;71(18):2435-44. ) ) [4] => SimpleXMLElement Object ( [Title] => Cates 2004 [Reference] => SimpleXMLElement Object ( [Citation] => Cates C. EBM Web Site. Visual Rx Version 3 (accessed October 2011) [Computer program]. Available from: www.nntonline.net/visualrx 2004. ) ) [5] => SimpleXMLElement Object ( [Title] => Cheema 2001 [Reference] => SimpleXMLElement Object ( [Citation] => Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis and Rheumatism 2001;44:1313–9. ) ) [6] => SimpleXMLElement Object ( [Title] => Collins 2006 [Reference] => SimpleXMLElement Object ( [Citation] => Collins CE, Gavin AL, Migone T-S, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Research and Therapy 2006;8:R6. ) ) [7] => SimpleXMLElement Object ( [Title] => Crow 2004 [Reference] => SimpleXMLElement Object ( [Citation] => Crow M, Kirou KA. Interferon-alpha in systemic lupus erythematosus. Current Opinion in Rheumatology 2004;16:541-7. ) ) [8] => SimpleXMLElement Object ( [Title] => Crowley 2005 [Reference] => SimpleXMLElement Object ( [Citation] => Crowley JE, Treml LS, Stadanlick JE, Carpenter E, Cancro MP. Homeostatic niche specification among naive and activated B cells: a growing role for the BLyS family of receptors and ligands. Seminars in Immunology 2005;17(3):193-9. ) ) [9] => SimpleXMLElement Object ( [Title] => Deeks 2011 [Reference] => SimpleXMLElement Object ( [Citation] => Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org. ) ) [10] => SimpleXMLElement Object ( [Title] => GRADEpro GDT [Computer program] [Reference] => SimpleXMLElement Object ( [Citation] => McMaster University (developed by Evidence Prime) GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), Accessed October 2019. Available at gradepro.org. ) ) [11] => SimpleXMLElement Object ( [Title] => Hay 1993 [Reference] => SimpleXMLElement Object ( [Citation] => Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Quarterly Journal of Medicine 1993;86(7):447-58. ) ) [12] => SimpleXMLElement Object ( [Title] => Higgins 2020 [Reference] => SimpleXMLElement Object ( [Citation] => Higgins JPT,  Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020.. Available from www.training.cochrane.org/handbook.. ) ) [13] => SimpleXMLElement Object ( [Title] => Hochberg 1997 [Reference] => SimpleXMLElement Object ( [Citation] => Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism 1997;40(9):1725. ) ) [14] => SimpleXMLElement Object ( [Title] => Isenberg 2000 [Reference] => SimpleXMLElement Object ( [Citation] => Isenberg DA, Gordon C. From BILAG to BLIPS - disease activity assessment in lupus past, present and future. Lupus 2000;9(9):651-4. ) ) [15] => SimpleXMLElement Object ( [Title] => Kandala 2013 [Reference] => SimpleXMLElement Object ( [Citation] => Kandala NB, Connock M, Grove A, Sutcliffe P, Mohiuddin S, Hartley L, et al. Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. BMJ Open 2013;3(7):1-12. ) ) [16] => SimpleXMLElement Object ( [Title] => Kim 2009 [Reference] => SimpleXMLElement Object ( [Citation] => Kim WU, Sreih A, Bucala R. Toll-like receptors in systemic lupus erythematosus prospects for therapeutic intervention. Autoimmunity Reviews 2009;8:204–8. ) ) [17] => SimpleXMLElement Object ( [Title] => Kim 2012 [Reference] => SimpleXMLElement Object ( [Citation] => Kim SS, Kirou KA, Erkan D. Belimumab in systemic lupus erythematosus: an update for clinicians. Therapeutic Advances in Chronic Disease 2012;3(1):11-23. ) ) [18] => SimpleXMLElement Object ( [Title] => Lee 2018 [Reference] => SimpleXMLElement Object ( [Citation] => Lee YH, Song GG. Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials. Lupus 2018;27(1):112-119. ) ) [19] => SimpleXMLElement Object ( [Title] => Litinskiy 2002 [Reference] => SimpleXMLElement Object ( [Citation] => Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nature Immunology 2002;3:822–9. ) ) [20] => SimpleXMLElement Object ( [Title] => Petri 1999 [Reference] => SimpleXMLElement Object ( [Citation] => Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999;8(8):685-91. ) ) [21] => SimpleXMLElement Object ( [Title] => Petri 2005 [Reference] => SimpleXMLElement Object ( [Citation] => Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. New England Journal of Medicine 2005;353(24):2550-8. ) ) [22] => SimpleXMLElement Object ( [Title] => Petri 2008 [Reference] => SimpleXMLElement Object ( [Citation] => Petri M, Stohl W, Chatham W,  McCune WJ,  Chevrier M,  Ryel J,  et al. Association of plasma B-lymphocyte stimulator (BLyS) levels and disease activity in systemic lupus erythematosus. Arthritis and Rheumatism 2008;58:2453–9. ) ) [23] => SimpleXMLElement Object ( [Title] => Ravirajan 1996 [Reference] => SimpleXMLElement Object ( [Citation] => Ravirajan CT, Sarraf CE, Anilkumar TV, Golding MC, Alison MR, Isenberg D. An analysis of apoptosis in lymphoid organs and lupus disease in murine systemic lupus erythematosus (SLE). Clinical and Experimental Immunology 1996;105:306–12. ) ) [24] => SimpleXMLElement Object ( [Title] => Schunemann 2011a [Reference] => SimpleXMLElement Object ( [Citation] => Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. ) ) [25] => SimpleXMLElement Object ( [Title] => Schunemann 2011b [Reference] => SimpleXMLElement Object ( [Citation] => Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. ) ) ) ) [4] => SimpleXMLElement Object ( [Title] => References to other published versions of this review [ReferenceList] => SimpleXMLElement Object ( [Title] => Singh 2013 [Reference] => SimpleXMLElement Object ( [Citation] => Singh  JA, Noorbaloochi  S, Tucker  MD. Belimumab for systemic lupus erythematosus.. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No: CD010668. [DOI: 10.1002/14651858.CD010668] ) ) ) ) ) ) ) [2] => SimpleXMLElement Object ( [MedlineCitation] => SimpleXMLElement Object ( [@attributes] => Array ( [Status] => Publisher [Owner] => NLM ) [PMID] => 33631840 [DateRevised] => SimpleXMLElement Object ( [Year] => 2021 [Month] => 02 [Day] => 25 ) [Article] => SimpleXMLElement Object ( [@attributes] => Array ( [PubModel] => Print-Electronic ) [Journal] => SimpleXMLElement Object ( [ISSN] => 1447-0756 [JournalIssue] => SimpleXMLElement Object ( [@attributes] => Array ( [CitedMedium] => Internet ) [PubDate] => SimpleXMLElement Object ( [Year] => 2021 [Month] => Feb [Day] => 25 ) ) [Title] => The journal of obstetrics and gynaecology research [ISOAbbreviation] => J Obstet Gynaecol Res ) [ArticleTitle] => Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study. [ELocationID] => 10.1111/jog.14709 [Abstract] => SimpleXMLElement Object ( [AbstractText] => Array ( [0] => To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control. [1] => Pregnancy outcome data were obtained for women at two Japanese facilities that provide counseling on drug use during pregnancy between April 1988 and December 2017. The incidence of major malformation was calculated among infants born to women taking domperidone (n = 519), nonteratogenic drugs (control, n = 1673), or metoclopramide (reference, n = 241) during the first trimester of pregnancy. Using the control group as reference, the crude odds ratio (OR) of the incidence of major malformation in the domperidone and metoclopramide groups was calculated using univariable logistic regression analysis. Adjusted OR was also calculated using multivariable logistic regression analysis adjusted for various other factors. [2] => The incidence of major malformation was 2.9% (14/485, 95% confidence interval [CI]: 1.6-4.8) in the domperidone group, 1.7% (27/1554, 95%CI: 1.1-2.5) in the control group, and 3.6% (8/224, 95%CI: 1.6-6.9) in the metoclopramide group. The adjusted multivariable logistic regression analysis showed no significant difference in incidence between the control and domperidone groups (adjusted OR: 1.86 [95%CI: 0.73-4.70], p = 0.191) or between the control and metoclopramide groups (adjusted OR: 2.20 [95%CI: 0.69-6.98], p = 0.183). [3] => This observational cohort study showed that domperidone exposure during the first trimester was not associated with increased risk of major malformation in infants. These results may help alleviate the anxiety of patients who took domperidone during pregnancy. ) [CopyrightInformation] => © 2021 The Authors. Journal of Obstetrics and Gynaecology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Obstetrics and Gynecology. ) [AuthorList] => SimpleXMLElement Object ( [@attributes] => Array ( [CompleteYN] => Y ) [Author] => Array ( [0] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Hishinuma [ForeName] => Kayoko [Initials] => K [Identifier] => https://orcid.org/0000-0003-1916-3726 [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Pharmacy, Toranomon Hospital, Minato-ku, Tokyo, Japan. ) ) [1] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Yamane [ForeName] => Ritsuko [Initials] => R [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Pharmacy, Toranomon Hospital, Minato-ku, Tokyo, Japan. ) ) [2] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Yokoo [ForeName] => Ikuko [Initials] => I [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Obstetrics and Gynecology, Toranomon Hospital, Minato-ku, Tokyo, Japan. ) ) [3] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Arimoto [ForeName] => Takahide [Initials] => T [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Obstetrics and Gynecology, Toranomon Hospital, Minato-ku, Tokyo, Japan. ) ) [4] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Takahashi [ForeName] => Kunihiko [Initials] => K [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Biostatistics, M&D Data Science Center, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan. ) ) [5] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Goto [ForeName] => Mikako [Initials] => M [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => The Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan. ) ) [6] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Saito [ForeName] => Yoshiyuki [Initials] => Y [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Human Health Sciences, Kyoto University Graduate School of Medicine, Sakyo-ku, Tokyo, Japan. ) ) [7] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Nakajima [ForeName] => Ken [Initials] => K [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Pharmacy, Yokohama Minami Kyousai Hospital, Yokohama, Kanagawa, Japan. ) ) [8] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Murashima [ForeName] => Atsuko [Initials] => A [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Center of Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan. ) ) [9] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Hayashi [ForeName] => Masahiro [Initials] => M [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Pharmacy, Toranomon Hospital, Minato-ku, Tokyo, Japan. ) ) ) ) [Language] => eng [GrantList] => SimpleXMLElement Object ( [@attributes] => Array ( [CompleteYN] => Y ) [Grant] => SimpleXMLElement Object ( [Agency] => Research and Development [Country] => SimpleXMLElement Object ( ) ) ) [PublicationTypeList] => SimpleXMLElement Object ( [PublicationType] => Journal Article ) [ArticleDate] => SimpleXMLElement Object ( [@attributes] => Array ( [DateType] => Electronic ) [Year] => 2021 [Month] => 02 [Day] => 25 ) ) [MedlineJournalInfo] => SimpleXMLElement Object ( [Country] => Australia [MedlineTA] => J Obstet Gynaecol Res [NlmUniqueID] => 9612761 [ISSNLinking] => 1341-8076 ) [CitationSubset] => IM [KeywordList] => SimpleXMLElement Object ( [@attributes] => Array ( [Owner] => NOTNLM ) [Keyword] => Array ( [0] => domperidone [1] => first trimester [2] => observational cohort study [3] => pregnancy outcomes [4] => teratogenicity ) ) ) [PubmedData] => SimpleXMLElement Object ( [History] => SimpleXMLElement Object ( [PubMedPubDate] => Array ( [0] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => received ) [Year] => 2020 [Month] => 05 [Day] => 12 ) [1] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => revised ) [Year] => 2020 [Month] => 12 [Day] => 02 ) [2] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => accepted ) [Year] => 2021 [Month] => 01 [Day] => 29 ) [3] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => entrez ) [Year] => 2021 [Month] => 2 [Day] => 25 [Hour] => 20 [Minute] => 19 ) [4] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => pubmed ) [Year] => 2021 [Month] => 2 [Day] => 26 [Hour] => 6 [Minute] => 0 ) [5] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => medline ) [Year] => 2021 [Month] => 2 [Day] => 26 [Hour] => 6 [Minute] => 0 ) ) ) [PublicationStatus] => aheadofprint [ArticleIdList] => SimpleXMLElement Object ( [ArticleId] => Array ( [0] => 33631840 [1] => 10.1111/jog.14709 ) ) [ReferenceList] => SimpleXMLElement Object ( [Title] => References [Reference] => Array ( [0] => SimpleXMLElement Object ( [Citation] => Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med. 2009;360:2528-35. ) [1] => SimpleXMLElement Object ( [Citation] => Pasternak B, Svanström H, Mølgaard-Nielsen D, Melbye M, Hviid A. Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. JAMA. 2013;310(15):1601-11. ) [2] => SimpleXMLElement Object ( [Citation] => Choi JS, Han JY, Ahn HK, Ryu HM, Kim MY, Yang JH, et al. Fetal and neonatal outcomes in women taking domperidone during pregnancy. J Obstet Gynaecol. 2013;33:160-2. ) [3] => SimpleXMLElement Object ( [Citation] => Cottin J, Beghin D, Jonville-Bera AP, et al. First trimester exposure to domperidone: a comparative prospective study of exposed infants. Reprod Toxicol. 2015;57:217. ) [4] => SimpleXMLElement Object ( [Citation] => Bérard A, Abbas-Chorfa F, Kassai B, Vial T, Nguyen KA, Sheehy O, et al. The French pregnancy cohort: medication use during pregnancy in the French population. PLoS One. 2019;14(7):e0219095. ) [5] => SimpleXMLElement Object ( [Citation] => Habermann F, Fritzsche J, Fuhlbrück F, Wacker E, Allignol A, Weber-Schoendorfer C, et al. Atypical antipsychotic drugs and pregnancy outcome a prospective, cohort study. J Clin Psychopharmacol. 2013;33(4):453-62. ) [6] => SimpleXMLElement Object ( [Citation] => EUROCAT Guide 1.4 and Reference Documents (Last update version 15/11/2019). Available from https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/JRC-EUROCAT-Full-Guide-1.4-version-15-Nov-2019.pdf ) [7] => SimpleXMLElement Object ( [Citation] => Japan Society of obstetrics and gynecology, Japan Gynecologist Association (eds) The clinical guidelines for gynecology and obstetrics (obstetrics portion) 2017. Tokyo: Japan Society of obstetrics and gynecology; 2017. ) ) ) ) ) [3] => SimpleXMLElement Object ( [MedlineCitation] => SimpleXMLElement Object ( [@attributes] => Array ( [Status] => Publisher [Owner] => NLM ) [PMID] => 33631816 [DateRevised] => SimpleXMLElement Object ( [Year] => 2021 [Month] => 02 [Day] => 25 ) [Article] => SimpleXMLElement Object ( [@attributes] => Array ( [PubModel] => Print ) [Journal] => SimpleXMLElement Object ( [ISSN] => 1532-2548 [JournalIssue] => SimpleXMLElement Object ( [@attributes] => Array ( [CitedMedium] => Internet ) [Volume] => 185 [Issue] => 1 [PubDate] => SimpleXMLElement Object ( [Year] => 2021 [Month] => Feb [Day] => 25 ) ) [Title] => Plant physiology [ISOAbbreviation] => Plant Physiol ) [ArticleTitle] => ASPB welcomes Oxford University Press. [Pagination] => SimpleXMLElement Object ( [MedlinePgn] => 15 ) [ELocationID] => 10.1093/plphys/kiaa025 [AuthorList] => SimpleXMLElement Object ( [@attributes] => Array ( [CompleteYN] => Y ) [Author] => Array ( [0] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Blatt [ForeName] => Michael R [Initials] => MR [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Laboratory of Plant Physiology and Biophysics, Bower Building, University of Glasgow, Glasgow G12 8QQ UK. ) ) [1] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Meyers [ForeName] => Blake C [Initials] => BC [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Donald Danforth Plant Science Center, Columbia MO, USA. ) ) ) ) [Language] => eng [PublicationTypeList] => SimpleXMLElement Object ( [PublicationType] => Journal Article ) ) [MedlineJournalInfo] => SimpleXMLElement Object ( [Country] => United States [MedlineTA] => Plant Physiol [NlmUniqueID] => 0401224 [ISSNLinking] => 0032-0889 ) [CitationSubset] => IM ) [PubmedData] => SimpleXMLElement Object ( [History] => SimpleXMLElement Object ( [PubMedPubDate] => Array ( [0] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => entrez ) [Year] => 2021 [Month] => 2 [Day] => 25 [Hour] => 20 [Minute] => 19 ) [1] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => pubmed ) [Year] => 2021 [Month] => 2 [Day] => 26 [Hour] => 6 [Minute] => 0 ) [2] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => medline ) [Year] => 2021 [Month] => 2 [Day] => 26 [Hour] => 6 [Minute] => 0 ) ) ) [PublicationStatus] => ppublish [ArticleIdList] => SimpleXMLElement Object ( [ArticleId] => Array ( [0] => 33631816 [1] => 6150006 [2] => 10.1093/plphys/kiaa025 ) ) ) ) [4] => SimpleXMLElement Object ( [MedlineCitation] => SimpleXMLElement Object ( [@attributes] => Array ( [Status] => Publisher [Owner] => NLM ) [PMID] => 33631811 [DateRevised] => SimpleXMLElement Object ( [Year] => 2021 [Month] => 02 [Day] => 25 ) [Article] => SimpleXMLElement Object ( [@attributes] => Array ( [PubModel] => Print ) [Journal] => SimpleXMLElement Object ( [ISSN] => 1532-2548 [JournalIssue] => SimpleXMLElement Object ( [@attributes] => Array ( [CitedMedium] => Internet ) [Volume] => 185 [Issue] => 1 [PubDate] => SimpleXMLElement Object ( [Year] => 2021 [Month] => Feb [Day] => 25 ) ) [Title] => Plant physiology [ISOAbbreviation] => Plant Physiol ) [ArticleTitle] => Stomatal, mesophyll conductance, and biochemical limitations to photosynthesis during induction. [Pagination] => SimpleXMLElement Object ( [MedlinePgn] => 146-160 ) [ELocationID] => 10.1093/plphys/kiaa011 [Abstract] => SimpleXMLElement Object ( [AbstractText] => The dynamics of leaf photosynthesis in fluctuating light affects carbon gain by plants. Mesophyll conductance (gm) limits CO2 assimilation rate (A) under the steady state, but the extent of this limitation under non-steady-state conditions is unknown. In the present study, we aimed to characterize the dynamics of gm and the limitations to A imposed by gas diffusional and biochemical processes under fluctuating light. The induction responses of A, stomatal conductance (gs), gm, and the maximum rate of RuBP carboxylation (Vcmax) or electron transport (J) were investigated in Arabidopsis (Arabidopsis thaliana (L.)) and tobacco (Nicotiana tabacum L.). We first characterized gm induction after a change from darkness to light. Each limitation to A imposed by gm, gs and Vcmax or J was significant during induction, indicating that gas diffusional and biochemical processes limit photosynthesis. Initially, gs imposed the greatest limitation to A, showing the slowest response under high light after long and short periods of darkness, assuming RuBP-carboxylation limitation. However, if RuBP-regeneration limitation was assumed, then J imposed the greatest limitation. gm did not vary much following short interruptions to light. The limitation to A imposed by gm was the smallest of all the limitations for most of the induction phase. This suggests that altering induction kinetics of mesophyll conductance would have little impact on A following a change in light. To enhance the carbon gain by plants under naturally dynamic light environments, attention should therefore be focused on faster stomatal opening or activation of electron transport. [CopyrightInformation] => © American Society of Plant Biologists 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com. ) [AuthorList] => SimpleXMLElement Object ( [@attributes] => Array ( [CompleteYN] => Y ) [Author] => Array ( [0] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Sakoda [ForeName] => Kazuma [Initials] => K [AffiliationInfo] => Array ( [0] => SimpleXMLElement Object ( [Affiliation] => Graduate School of Agricultural and Life Sciences, University of Tokyo, Nishitokyo 188-0002, Tokyo, Japan. ) [1] => SimpleXMLElement Object ( [Affiliation] => Research Fellow of Japan Society for the Promotion of Science, Tokyo, Japan. ) ) ) [1] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Yamori [ForeName] => Wataru [Initials] => W [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Graduate School of Agricultural and Life Sciences, University of Tokyo, Nishitokyo 188-0002, Tokyo, Japan. ) ) [2] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Groszmann [ForeName] => Michael [Initials] => M [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Division of Plant Science, Research School of Biology, The Australian National University, Canberra, Territory 2601, Australia. ) ) [3] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Evans [ForeName] => John R [Initials] => JR [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Division of Plant Science, Research School of Biology, The Australian National University, Canberra, Territory 2601, Australia. ) ) ) ) [Language] => eng [PublicationTypeList] => SimpleXMLElement Object ( [PublicationType] => Journal Article ) ) [MedlineJournalInfo] => SimpleXMLElement Object ( [Country] => United States [MedlineTA] => Plant Physiol [NlmUniqueID] => 0401224 [ISSNLinking] => 0032-0889 ) [CitationSubset] => IM ) [PubmedData] => SimpleXMLElement Object ( [History] => SimpleXMLElement Object ( [PubMedPubDate] => Array ( [0] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => received ) [Year] => 2020 [Month] => 08 [Day] => 18 ) [1] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => accepted ) [Year] => 2020 [Month] => 10 [Day] => 22 ) [2] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => entrez ) [Year] => 2021 [Month] => 2 [Day] => 25 [Hour] => 20 [Minute] => 19 ) [3] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => pubmed ) [Year] => 2021 [Month] => 2 [Day] => 26 [Hour] => 6 [Minute] => 0 ) [4] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => medline ) [Year] => 2021 [Month] => 2 [Day] => 26 [Hour] => 6 [Minute] => 0 ) ) ) [PublicationStatus] => ppublish [ArticleIdList] => SimpleXMLElement Object ( [ArticleId] => Array ( [0] => 33631811 [1] => 6011081 [2] => 10.1093/plphys/kiaa011 ) ) ) ) [5] => SimpleXMLElement Object ( [MedlineCitation] => SimpleXMLElement Object ( [@attributes] => Array ( [Status] => Publisher [Owner] => NLM ) [PMID] => 33631807 [DateRevised] => SimpleXMLElement Object ( [Year] => 2021 [Month] => 02 [Day] => 25 ) [Article] => SimpleXMLElement Object ( [@attributes] => Array ( [PubModel] => Print ) [Journal] => SimpleXMLElement Object ( [ISSN] => 1532-2548 [JournalIssue] => SimpleXMLElement Object ( [@attributes] => Array ( [CitedMedium] => Internet ) [Volume] => 185 [Issue] => 1 [PubDate] => SimpleXMLElement Object ( [Year] => 2021 [Month] => Feb [Day] => 25 ) ) [Title] => Plant physiology [ISOAbbreviation] => Plant Physiol ) [ArticleTitle] => Co-overproducing Rubisco and Rubisco activase enhances photosynthesis in the optimal temperature range in rice. [Pagination] => SimpleXMLElement Object ( [MedlinePgn] => 108-119 ) [ELocationID] => 10.1093/plphys/kiaa026 [Abstract] => SimpleXMLElement Object ( [AbstractText] => Rubisco limits C3 photosynthesis under some conditions and is therefore a potential target for improving photosynthetic efficiency. The overproduction of Rubisco is often accompanied by a decline in Rubisco activation, and the protein ratio of Rubisco activase (RCA) to Rubisco (RCA/Rubisco) greatly decreases in Rubisco-overproducing plants (RBCS-ox). Here, we produced transgenic rice (Oryza sativa) plants co-overproducing both Rubisco and RCA (RBCS-RCA-ox). Rubisco content in RBCS-RCA-ox plants increased by 23%-44%, and RCA/Rubisco levels were similar or higher than those of wild-type plants. However, although the activation state of Rubisco in RBCS-RCA-ox plants was enhanced, the rates of CO2 assimilation at 25°C in RBCS-RCA-ox plants did not differ from that of wild-type plants. Alternatively, at a moderately high temperature (optimal range of 32°C-36°C), the rates of CO2 assimilation in RBCS-ox and RBCS-RCA-ox plants were higher than in wild-type plants under conditions equal to or lower than current atmospheric CO2 levels. The activation state of Rubisco in RBCS-RCA-ox remained higher than that of RBCS-ox plants, and activated Rubisco content in RCA overproducing, RBCS-ox, RBCS-RCA-ox, and wild-type plants was highly correlated with the initial slope of CO2 assimilation against intercellular CO2 pressures (A:Ci) at 36°C. Thus, a simultaneous increase in Rubisco and RCA contents leads to enhanced photosynthesis within the optimal temperature range. [CopyrightInformation] => © American Society of Plant Biologists 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com. ) [AuthorList] => SimpleXMLElement Object ( [@attributes] => Array ( [CompleteYN] => Y ) [Author] => Array ( [0] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Suganami [ForeName] => Mao [Initials] => M [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Graduate School of Agricultural Science, Tohoku University, Sendai 980-8572, Japan. ) ) [1] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Suzuki [ForeName] => Yuji [Initials] => Y [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Faculty of Agriculture, Iwate University, Morioka, Iwate 020-8550, Japan. ) ) [2] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Tazoe [ForeName] => Youshi [Initials] => Y [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Graduate School of Agricultural Science, Tohoku University, Sendai 980-8572, Japan. ) ) [3] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Yamori [ForeName] => Wataru [Initials] => W [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Graduate School of Agricultural Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan. ) ) [4] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Makino [ForeName] => Amane [Initials] => A [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Graduate School of Agricultural Science, Tohoku University, Sendai 980-8572, Japan. ) ) ) ) [Language] => eng [PublicationTypeList] => SimpleXMLElement Object ( [PublicationType] => Journal Article ) ) [MedlineJournalInfo] => SimpleXMLElement Object ( [Country] => United States [MedlineTA] => Plant Physiol [NlmUniqueID] => 0401224 [ISSNLinking] => 0032-0889 ) [CitationSubset] => IM ) [PubmedData] => SimpleXMLElement Object ( [History] => SimpleXMLElement Object ( [PubMedPubDate] => Array ( [0] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => received ) [Year] => 2020 [Month] => 09 [Day] => 11 ) [1] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => accepted ) [Year] => 2020 [Month] => 10 [Day] => 30 ) [2] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => entrez ) [Year] => 2021 [Month] => 2 [Day] => 25 [Hour] => 20 [Minute] => 19 ) [3] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => pubmed ) [Year] => 2021 [Month] => 2 [Day] => 26 [Hour] => 6 [Minute] => 0 ) [4] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => medline ) [Year] => 2021 [Month] => 2 [Day] => 26 [Hour] => 6 [Minute] => 0 ) ) ) [PublicationStatus] => ppublish [ArticleIdList] => SimpleXMLElement Object ( [ArticleId] => Array ( [0] => 33631807 [1] => 5998656 [2] => 10.1093/plphys/kiaa026 ) ) ) ) ) ) Haijun Tian | PubFacts

Publications by authors named "Haijun Tian"